Agalimmune Ltd.

https://www.agalimmune.com

Agalimmune Ltd. is a biopharmaceutical company with an innovative anti-cancer immunotherapy pipeline for generating a systemic, adaptive immune response to solid tumors. It was established in 2013 and is headquartered in London, England with laboratories in Sandwich, England and Boston, Massachusetts. AGI-134, Agalimmune's lead molecule is a synthetic alpha-Gal immunotherapy in development for solid tumors. AGI-134 harnesses the body's pre-existing, highly abundant, anti-alpha-Gal antibodies to induce a systemic, specific anti-tumor response to the patient's own tumor neo-antigens. This response not only kills the tumor cells at the site of injection, but also brings about a durable, follow-on anti-metastatic immune response. Alpha-Gal is a cell-surface carbohydrate antigen which is not expressed by humans, unlike virtually all other mammals and bacteria. Therefore, humans universally produce and maintain high levels of anti-Gal antibodies, due to exposure to alpha-Gal on bacteria in the digestive system. AGI-134 is injected into the tumor, where it coats the tumor cell membranes, resulting in alpha-Gal being exposed on the tumor cell surface. Anti-Gal antibodies bind to the alpha-Gal part of AGI-134 to produce an initial immune response that activates complement-dependent and antibody-dependent cellular cytotoxicity (cell death). This cytotoxicity generates immune-tagged cells and cellular debris that trigger an uptake of tumor-associated antigens by antigen-presenting cells (APCs). These APCs induce a follow-on systemic immune response by the activation and clonal expansion of T cells (CD8+) to the patient's own neo-antigens. This approach not only targets the primary injectable tumor, but has also demonstrated efficacy against existing distant secondary tumors. Furthermore, the mechanism of action suggests the potential of long-term protection against future metastases. The use of intratumoral alpha-Gal glycolipids to treat solid tumors was invented by Prof. Uri Galili, Ph.D., while at the University of Massachusetts, from where the intellectual property rights were licensed. The intellectual property rights relating to AGI-134 were in-licensed from KODE Biotech Ltd., the inventors of AGI-134. *

	Start	2013-04-25 established
	Group	BioLineRx (Group)
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Industry 2	Alphaject™ technology (alphagal coating of tumours)
	Person	Marron, Damian (Agalimmune 201603 CEO before TxCell + Cytheris + Trophos + NiCox + 3M + Orphan Europe)
	Person 2	Westby, Mike (Agalimmune 201406 CEO)

	Region	London, Greater London
	Country	United Kingdom (GB)
	Street	6 Cork Street Mayfair, 2nd Floor, Clarebell House
	City	W1S 3NX London
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: BioLineRx Ltd.. (3/23/17). "Press Release: BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline". Tel Aviv.

		Record changed: 2023-07-10